Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director · President and CEO | January 06, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date January 06, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2035-03-31 | Direct | 125,000 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 125,000 · Balance 125,000 F1: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 9, 2026 17:27 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-26-000036 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-03-31 F1 · shares: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:41 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-25-001354 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-20 F1 · shares: On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 19:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001731122-25-001246 · ownership.xml · derivative · entry 3 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,500 shares Expires 2025-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 19:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Tax withholdingCommon Stock | 145,048 | $9.58 | $1,389,559.84 |
DisclosureSEC source: 0001731122-25-001246 · ownership.xml · nonDerivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,510,165 F1 · shares: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on September 18, 2025. The reporting person received 42,452 shares of common stock on net exercise of an option to purchase 187,500 shares of common stock. The Company withheld 145,048 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the closing price on September 11, 2025 of $9.58, pursuant to the terms of the Company's 2015 Stock Option Plan. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 19:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 187,500 | $5.04 | $945,000.00 |
DisclosureSEC source: 0001731122-25-001246 · ownership.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,655,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 17:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-25-001167 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-03-31 F1 · shares: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-25-000654 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-03-31 F1 · shares: On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001731122-25-000452 · ownership.xml · derivative · entry 3 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2025-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Tax withholdingCommon Stock | 282,497 | $9.63 | $2,720,446.11 |
DisclosureSEC source: 0001731122-25-000452 · ownership.xml · nonDerivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,467,713 F1 · shares: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on April 2, 2025. The reporting person received 217,503 shares of common stock on net exercise of an option to purchase 500,000 shares of common stock. The Company withheld 282,497 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the average of the high and low sales price on March 24, 2025 of $9.63, pursuant to the terms of the Company's 2007 Stock Option Plan. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 500,000 | $0.92 | $460,000.00 |
DisclosureSEC source: 0001731122-25-000452 · ownership.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:14 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-25-000096 · ownership.xml · derivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-06-14 F2 · shares: On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:14 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 166,666 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001731122-25-000096 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,000 Underlying: Common Stock · 166,000 shares Expires 2032-06-14 F1 · shares: On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-24-002044 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-20 F1 · shares: On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| November 19, 2024 Filed Dec 6, 2024 21:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-24-001953 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 125,000 shares Expires 2032-06-27 F1 · shares: On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,380 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001731122-24-000552 · ownership.xml · derivative · entry 3 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,380 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 73,380 | $5.11 | $374,971.80 |
DisclosureSEC source: 0001731122-24-000552 · ownership.xml · nonDerivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,210 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 73,380 | $1.32 | $96,861.60 |
DisclosureSEC source: 0001731122-24-000552 · ownership.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 12, 2024 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-24-000070 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-06-27 F1 · balance_after: On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 232,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001731122-23-001246 · ownership.xml · derivative · entry 5 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 232,000 shares Expires 2023-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 232,000 | $1.60 | $371,200.00 |
DisclosureSEC source: 0001731122-23-001246 · ownership.xml · nonDerivative · entry 3 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 268,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001731122-23-001246 · ownership.xml · derivative · entry 4 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 268,000 shares Expires 2023-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 268,000 | $7.98 | $2,139,310.00 |
DisclosureSEC source: 0001731122-23-001246 · ownership.xml · nonDerivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,018,210 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 268,000 | $1.60 | $428,800.00 |
DisclosureSEC source: 0001731122-23-001246 · ownership.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,286,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:19 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001731122-21-001292 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-08-02 F1 · derivative.exercise_date: The options shall vest upon achieving a key enrollment milestone in a late stage clinical study. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:48 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,620 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001731122-21-001127 · ownership.xml · derivative · entry 3 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,380 Underlying: Common Stock · 51,620 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options subject to this grant vested over 4 years on May 8, 2015, May 8, 2016, May 8, 2017, May 8, 2018. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:48 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 51,620 | $26.00 | $1,342,120.00 |
DisclosureSEC source: 0001731122-21-001127 · ownership.xml · nonDerivative · entry 2 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,210 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:48 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 51,620 | $1.32 | $68,138.40 |
DisclosureSEC source: 0001731122-21-001127 · ownership.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 14:17 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000004 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common stock · 550,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2/3 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 18:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000021 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| May 03, 2019 Filed May 7, 2019 16:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001615774-19-007213 · s118064_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common stock · 750,000 shares Expires 2029-05-03 F1 · derivative.exercise_date: The options shall vest as to 250,000 on July 5, 2020, 250,000 on July 5, 2021 and 250,000 on July 5, 2022. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 409,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010443 · s113106_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,500 Underlying: Common Stock · 409,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| May 15, 2018 Filed May 17, 2018 17:16 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001615774-18-004019 · s110299_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 15:16 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 1,360 | $2.92 | $3,971.20 |
DisclosureSEC source: 0001615774-18-001744 · s109283_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,210 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 11:01 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 1,450 | $2.73 | $3,958.50 |
DisclosureSEC source: 0001615774-18-001650 · s109262_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,850 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 14:06 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 1,500 | $2.63 | $3,945.00 |
DisclosureSEC source: 0001615774-18-001629 · s109254_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,400 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 08:56 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 1,650 | $2.41 | $3,976.50 |
DisclosureSEC source: 0001615774-18-001587 · s109234_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · Director, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,900 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001615774-17-007355 · s108449_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on March 31, 2018. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 14:49 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.39 | $1,646.25 |
DisclosureSEC source: 0001615774-17-005929 · s107870_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,250 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 24, 2017 Filed Oct 24, 2017 12:05 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.92 | $1,845.00 |
DisclosureSEC source: 0001615774-17-005861 · s107842_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,875 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 19, 2017 Filed Oct 19, 2017 18:46 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.49 | $1,683.75 |
DisclosureSEC source: 0001615774-17-005807 · s107803_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,500 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 09:46 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.27 | $1,601.25 |
DisclosureSEC source: 0001615774-17-005767 · s107769_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,125 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 11:06 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 750 | $4.22 | $3,165.00 |
DisclosureSEC source: 0001615774-17-005731 · s107755_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,750 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 17:56 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.30 | $1,612.50 |
DisclosureSEC source: 0001615774-17-005604 · s107704_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,000 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 19:52 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.20 | $1,575.00 |
DisclosureSEC source: 0001615774-17-005508 · s107663_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,625 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 14:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.21 | $1,578.75 |
DisclosureSEC source: 0001615774-17-005440 · s107643_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,250 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 26, 2017 Filed Sep 26, 2017 15:07 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $3.88 | $1,455.00 |
DisclosureSEC source: 0001615774-17-005351 · s107605_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,875 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 20, 2017 Filed Sep 20, 2017 16:50 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.23 | $1,586.25 |
DisclosureSEC source: 0001615774-17-005226 · s107562_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,500 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 13:58 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.40 | $1,650.00 |
DisclosureSEC source: 0001615774-17-005183 · s107540_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,125 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 14:27 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.58 | $1,717.50 |
DisclosureSEC source: 0001615774-17-005088 · s107514_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,750 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 11, 2017 Filed Sep 11, 2017 20:49 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.81 | $1,803.75 |
DisclosureSEC source: 0001615774-17-005014 · s107463_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,375 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.